title: Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
abstract: Although calcineurin inhibitor drugs have been the mostly used therapy in modern immunosuppression in kidney transplantation, their effect on kidney allograft dysfunction has been suboptimal as far as preservation of kidney function is concerned. Additionally, there are metabolic and other nonmetabolic effects including increased risk of malignancy that has necessitated the use of mammalian target of rapamycin inhibitors to reduce exposure to calcineurin inhibitors. Mammalian target of rapamycin inhibitors, both sirolimus and everolimus, have been studied in several trials to facilitate preservation of kidney function with variable effects on kidney allograft function and immunogenicity. Preservation of kidney function is increasingly becoming the mainstay of immunosuppression not only in kidney transplantation, but also in extrakidney transplantation. The best kidney outcomes have been reported in calcineurin inhibitor withdrawal studies using mammalian target of rapamycin inhibitors, in kidney transplant recipients with stable kidney function. This review article summarizes data from several studies in which mammalian target of rapamycin inhibitors have been used to reduce exposure to or withdraw calcineurin inhibitors in an attempt to preserve kidney function.
authors.affiliation: Division of Nephrology and Hypertension and the Transplant Institute, University Hospitals Case Medical Center, Cleveland, OH.
authors.forename: Joshua
authors.initials: J
authors.lastname: Augustine
authors.affiliation: Division of Nephrology and Hypertension and the Transplant Institute, University Hospitals Case Medical Center, Cleveland, OH. Electronic address: Donald.hricik@UHhospitals.org.
authors.forename: Donald E
authors.initials: DE
authors.lastname: Hricik
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D000818:Animals; D065095:Calcineurin Inhibitors / Q000627:therapeutic use*; D006084:Graft Rejection / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors*; D016030:Kidney Transplantation; D020123:Sirolimus / Q000037:antagonists & inhibitors*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus
keywords: Calcineurin inhibitors; Inhibitors; Kidney transplantation; Target of rapamycin